- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed shareholders approve demerger
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while theenergy unit will be called Hafslund ASA. Nycomed shares will betraded on the Oslo, London, and Copenhagen exchanges, while NycomedAmerican Depository Receipts will be listed on the New York StockExchange under the symbol "NYD."
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
